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Abstract
Diabetes is a major health disorder affecting millions of people worldwide.  
Numerous studies have confirmed that micro and macrovascular complications 
ensue as a result of hyperglycemia. Initial studies show that while intensive glycemic 
control has been shown to reduce microvascular complications in both type 1 and 2 
diabetics, macrovascular benefits have only been clearly seen in type 1 diabetics.  
Conflicting results have emerged regarding the benefits and potential adverse effects 
of tight glycemic control.   Recent studies have emerged demonstrating some 
macrovascular benefits in type 2 diabetics, though this was associated with increased 
risk of hypoglycemia in some individuals.  Thus, glycemic control in individuals 
with diabetes may need to be individualized in order to maximize benefits while 
minimizing adverse effects.
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Résumé
Le diabète est un grave trouble de santé affectant des millions de personnes dans le 
monde entier. De nombreuses études ont confirmé que les micro et complications 
macrovasculaires découler d' hyperglycémie. Études préliminaires montrent que, 
bien que intensives de contrôle de la glycémie a été montré à réduire  les 
complications microvasculaires dans le type 1 et 2, les diabétiques macrovasculaires 
avantages n'ont été clairement perçu dans les diabétiques de type 1. Résultats 
contradictoires ont vu le jour en ce qui concerne les avantages et les effets 
indésirables potentiels de serré de contrôle de la glycémie .   De récentes études ont 
émergé démontrant certaines  prestations macroangiopathie diabétiques de type 2, 
même si c'était associé à une augmentation du risque d'hypoglycémie  chez certains 
individus. Ainsi, de contrôle de la glycémie chez les personnes diabétiques peuvent 
avoir besoin d'être individualisée afin d'en maximiser les avantages tout en 
minimisant les effets indésirables.
Mots-clés     contrôle glycémique Diabète Le diabète de type 2 N·m glucose
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Clinical Trial Acronyms
ACCORD A c t i o n  t o  C o n t r o l  
Cardiovascular Risk in 
Diabetes
ADVANCE Action in Diabetes and 
Vascular Disease: Preterax 
and Diamicron Modified 
R e l e a s e  C o n t r o l l e d  
Evaluation
DCCT D i a b e t e s  C o n t r o l  a n d  
Complications Trial
NICE-SUGARNormoglycemia in Intensive 
Care Evaluation and Survival 
using Glucose Algorithm 
Regulation
UKPDS United Kingdom Prospective 
Diabetes Trial
VADT Veterans Affairs Diabetes 
Trial
VISEP Volume Substitution and 
Insulin Therapy in Severe 
Sepsis
Introduction
Diabetes is a chronic disease 
occurring as a result of insufficient insulin 
production by the pancreas or ineffective use 
of the insulin produced by the pancreas (1).  A 
glycated hemoglobin (HbA1C) level of ≥
6.5% is required for diagnosing Diabetes 
according to the American Diabetes 
Association (ADA)(2).  Regardless of the 
type of diabetes (type 1 or 2) hyperglycemia 
is the end result.  It has been well documented 
that adverse macro and microvascular affects 
ensue from long term hyperglycemia (3).  
Diabetes doubles the risk of a wide range of 
vascular diseases and increases the risk of 
mortality (4).  Previous studies have shown 
that controlling hyperglycemia leads to 
favorable outcomes, however recent studies 
have emerged regarding safety issues 
associated with intense glycemic control in 
diabetes (5-8).  This article discuses findings 
of major studies involving glycemic control.
What is the rationale for controlling 
hyperglycemia in diabetic patients?
The Framingham study, published in 
1979, established a clear association between 
hyperglycemia and adverse outcomes in 
diabetic patients (9).   Cardiovascular 
disease is a major concern in those with 
diabetes mellitus and remains a leading cause 
of morbidity and mortality.  In 1993 the 
DCCT provided evidence that microvascular 
complications can be reduced in type 1 
diabetics by maintaining blood glucose at 
near-normal levels.  In this study 1,441 
patients were followed for a mean of 6.5 
years.  Patients were randomly assigned to 
either receive intensive therapy (an external 
insulin pump or 3 or more daily insulin 
injections) or conventional therapy with one 
or two insulin injections per day.  Results 
revealed that intensive therapy reduced the 
d e v e l o p m e n t  a n d  p r o g r e s s i o n  o f  
microvascular complications (retinopathy, 
neuropathy and nephropathy) with 
hypoglycemia as the main adverse effect.  
Twelve years later EDIC published an 
observational follow up to DCCT proving 
that macrovascular complications were also 
reduced in patients with type 1 diabetes who 
received intensive therapy (reduced risk of  
any cardiovascular disease by 42%, p=0.02) 
(10). It was inconclusive whether these 
findings would provide similar benefits in 
type 2 diabetics.  The UKPDS was designed 
to determine whether intensive glycemic 
control in type 2 diabetics would reduce the 
r i sk  of  micro  and macrovascular  
complications.  The study followed 5,102 
newly diagnosed type 2 diabetics for 10 years 
and found that those receiving intensive 
therapy (sulfonylureas or insulin) were less 
l i k e l y  t o  d e v e l o p  m i c r o v a s c u l a r  
complications compared to those receiving 
conventional therapy (diet alone).  However, 
no macrovascular benefits were noted in the 
intensive therapy group (11).  A subset of 753 
overweight patients in the UKPDS were 
assigned to receive metformin or 
conventional therapy, with results showing a 
36% decrease for all cause mortality in those 
receiving metformin.
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Are there any additional benefits of 
intensive glycemic control beyond 
microvascular protection?
Previous  s tudies  have  been  
successful in showing clear benefits of 
intense glycemic therapy in lowering the rate 
of microvascular complications, but are there 
any additional benefits?  Studies such as the 
ACCORD, ADVANCE and VADT aimed to 
determine the answer.  In the ACCORD 
study 10,251 patients with type 2 diabetes 
were enrolled in a RCT and randomly 
assigned to either an intensive therapy group 
with aims of HbA1C < 6% or a standard 
therapy group with an HbA1C aimed 
between 7-7.9%.  The study ended 
prematurely after 3.5 years due to a 22% 
higher mortality rate in the intensive therapy 
group.  No significant reduction in major 
cardiovascular events was noted.   After 
termination of the study those receiving 
intensive therapy were switched to standard 
therapy with a glycated hemoglobin goal of 
7-7.9% and followed for another 1.2 years.  
The trends remained consistent during the 
follow up period (intensive therapy group 
showed no significant difference compared 
to the standard therapy group in primary care 
outcomes but had more deaths from all cause 
mortality) (12).
The ADVANCE and VADT studies 
also randomized patients into intensive 
therapy or standard therapy.  The ADVANCE 
study enrolled 11,140 type 2 diabetics while 
the VADT study enrolled 1791.  Patients 
were followed up for 5 and 5.6 years in the 
ADVANCE and VADT, respectively (5,6).  
The primary end points were similar in both 
studies and included development of major 
cardiovascular outcomes.  Both studies 
failed to show a significant reduction in 
major cardiovascular events between the 
intensive therapy group compared to the 
standard therapy group. Both studies showed 
a reduction in microvascular complications 
in the intensive therapy group, consistent 
with the UKPDS.
The results of the above studies 
seemed to indicate that intensive glycemic 
control provides no benefit in type 2 
diabetics.  However, multiple limitations of 
these studies may have contributed to such 
outcomes.  With a premature termination at 
3.5 years for the ACCORD trial (although 
patient subsequently followed for an 
additional 1.2 years showed similar 
outcomes) and a 5 and 5.6 year follow up of 
the ADVANCE and VADT respectively, 
concerns as to whether sufficient follow up 
time had passed to detect any cardiovascular 
benefit are raised.   This concern may be 
further strengthened by the UKPDS trial in 
which no cardiovascular benefit was seen in 
the intensive control group within the first 10 
years, however an additional 10year 
monitoring (UKPDS 80) revealed a 
reduction in MI by 15% (P-0.01) and a 
reduction in all cause mortality by 13% (p-
0.007) (13).
Another limitation may be an 
inadequate sample size.  Despite negative 
results in individual trials meta-analysis 
showed conflicting results.  In 2009 a meta-
analyses by Ray et al, which included data 
from 5 studies (ACCORD, ADVANCE, 
VADT, UKPDS and PROactive) revealed a 
17% reduction in nonfatal MI within the 
intensive therapy group (14).  An additional 
analysis of the four RCT (ACCORD, 
ADVANCE, VADT and UKPDS) with over 
27,000 participants revealed a 9% reduction 
in cardiovascular events in the intensive 
therapy group.  These results were primarily 
due to a 15% decrease in the risk of MIs.  
Other meta-analysis showed similar results 
(14,15).  These results suggest that the 
benefits of intensive glycemic control may 
only be seen after prolonged duration and 
with a large number of participants. 
Additionally, the use of certain drugs 
may have contributed to the lack of expected 
cardiovascular benefits.  Evidence has been 
produced that the use of rosiglitazone, a 
thiazolidinedione, increases the risk of 
cardiovascular disease (16).  In the 
ACCORD trial 92% of participants in the 
intensive therapy group received this drug as 
compared to 58% in the standard therapy.  
Sulfonylureas were a major drug used in the 
intensive therapy of the ACCORD, 
ADVANCE and VADT, however previous 
studies have raised suspicion regarding the 
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increase cardiovascular risk associated with 
this drug (17-19).  Lastly, the use of insulin 
therapy itself may promote weight gain 
leading to an increase risk of developing 
cardiovascular disease.
Is there increased risk of harm when 
intensive glycemic control is the goal?
Indeed there are many benefits of 
intense glycemic control, most notably a 
decrease in microvascular events, but 
adverse effects are also of major concern.  
One of the greatest concerns regarding 
intense glycemic control resides in the 
development of hypoglycemia, particularly 
with the use of insulin treatment.  
Hypoglycemia itself can result in sudden 
death, myocardial ischemia and arrhythmias 
(20-22) .  The  use  o f  insu l in  and  
thiazolidinediones in the intensive therapy in 
the ACCORD trial may explain the 3.5kg 
weight gain seen in this group.  A meta-
analysis of 33,040 found that participants 
receiving intensive therapy were 2.5 kg 
heavier than those receiving standard therapy 
(14).
Should Glycemic Control in Type 2 
Diabetic Patients Be Individualized?
Approximately 347 million people are 
affected by diabetes worldwide (23). 
Hyperglycemia has been linked to micro and 
macrovascular complications and should be 
the aim in treating diabetics.  Studies have 
been successful in showing clear benefits of 
intensive glycemic control in type 2 
diabetics, however these studies have also 
shown adverse effects.  Organizations such 
as the American Diabetes Association (ADA) 
recommend an HbA1C level of less than 6.5 
(24).  Many patients receive multiple drugs, 
often a mixture of insulin and oral agents to 
achieve such targets.  These organizations 
however also recognize that targets should be 
individualized.  
One treatment regimen may provide 
benefit to one patient while harming another.  
When employing a treatment strategy certain 
factors within each patient's profile should be 
taken into consideration.  
New recommendations by the Canadian 
Diabetes Association state that where as an 
HbA1C <7% should be adequate for most 
type 1 and 2 diabetics to lower the risk of 
complications, a greater range of 7.1-8.5% 
may provide greater benefit for a certain 
patient profile including those with limited 
life expectancy, multiple co-morbidities, and 
a history of recurrent severe hypoglycemia 
(25) .  A study by Reaven et al. (26) used 
coronary artery calcium (CAC) to assess 
whether cardiovascular outcomes where 
i n f l u e n c e d  b y  b a s e l i n e  c o r o n a r y  
atherosclerosis following intensive glycemic 
treatment in the VADT study.  The study 
revealed that cardiovascular events were 
decreased among those receiving intensive 
therapy with a CAC score ≤100 compared to 
those in the intensive therapy group with a 
CAC score ≥100.  Similar findings were 
seen in a meta-analysis by Turnbull et al (27) 
in which those with no history of 
macrovascular disease achieved benefits 
while receiving intensive therapy as 
compared to those with a prior history of 
macrovascular disease in which no benefit 
was achieved. These studies suggest that 
individualizing glycemic control may not 
only be beneficial but crucial in maximizing 
benefits while minimizing risks and that 
many other factors should be explored as 
possible exclusion criteria in those receiving 
intensive therapy.
What is New in the Management of 
Hyperglycemia in Acutely ill Patient?
Hyperglycemia is by no means a rare 
occurrence in the inpatient setting.  Most 
causes of inpatient hyperglycemia can be 
attributed to diagnosed or undiagnosed 
diabetes as well as stressed induced 
hyperglycemia.  Both are associated with 
poor outcomes and should be a major concern 
to physicians.   The balance between 
controlling glucose while avoiding 
hypoglycemia can be a challenging task for 
many physicians.  Prior studies have shown 
improved outcomes associated with the 
treatment of hyperglycemia in hospitalized 
patients (28-30).  A study by Van den Berghe 
et al randomized critically ill patients to 
Lessons learned from glycemia control studies            Cunningham A and Dokun AO
Res. J. of Health Sci. Vol 2(3). July/Sept., 2014                                                           120
receive tight control or usual care and found a 
34% reduction in mortality in those receiving 
tight glycemic control (28).  The American 
Association of Clinical Endocrinologist 
(AACE), American Diabetes Association 
(ADA) and the American College of 
Endocrinology have since established 
recommendations for treatment of inpatient 
hyperglycemia (31).  
Findings similar to Van den Berghe et 
al have been described (30,32), however 
conflicting results have been found in other 
studies (8,33-35).    One of these studies, 
VISEP, evaluated the effects of intensive 
insulin therapy in patients with severe sepsis 
and found the rate of severe hypoglycemia (≤ 
40mg per deciliter) to be higher in the 
intensive therapy group (P<0.001) in 
addition to the rate of serious adverse event 
(P=0.01) (34).  A larger study, NICE-
SUGAR, randomized 3,054 critically ill 
patients to receive intensive glucose control 
(with a blood glucose aim of 81-108mg per 
deciliter) and 3,050 critically ill patients to 
receive conventional control (with a target 
glucose of ≤ 180mg per deciliter).   Similar to 
the VISEP trial, the intensive insulin therapy 
was associated with a higher rate of 
hypoglycemia as compared to the 
conventional therapy group (P<0.001).  Of 
the total deaths (829), 27.5% received 
intensive therapy vs. 24.9% who received 
conventional therapy (P=0.02).  A meta-
analysis of 26 trials of 13,567 patients 
including the NICE-SUGAR study suggests 
a mortality benefit for critically ill surgical 
patients rather than medical patients.
The most recent updates by the ADA and 
AACE suggest that insulin infusion should 
be used to control hyperglycemia in critically 
ill patients in the ICU, with an initial 
threshold of ≤180mg/dl until the initiation of 
intravenous insulin.  Once IV insulin has 
commenced blood glucose levels should be 
maintained in the range of 140-180mg/dl. 
Conclusions 
Hyperglycemia is a major concern 
amongst physicians, particularly in regards 
to diabetics.  With this condition affecting 
millions of individuals worldwide much 
effort has been put into research regarding the 
best treatment strategies and target HbA1C.  
Regardless of the approach used to control 
blood sugar one thing appears consistent, 
minimizing adverse  effects  whi le  
maximizing benefits remains a key focus.  
No two patients are exactly the same and with 
so many patient profiles treatment should be 
individualized.  Clinicians should determine 
which therapy, whether intensive or standard, 
a patient will likely benefit most from.  
It is our belief that early detection along with 
continuous monitoring by concerned 
physicians will yield the greatest benefits.  
Treatment strategies such as diet and 
exercise, blood pressure and lipid control 
should be instituted.  Indeed a better 
understanding of such an important health 
issue is needed.  Future studies should aim to 
determine which therapies are beneficial and 
harmful to certain patient characteristics.
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